BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9580575)

  • 1. Dose-response analysis of opioid cross-tolerance and withdrawal suppression during LAAM maintenance.
    Houtsmuller EJ; Walsh SL; Schuh KJ; Johnson RE; Stitzer ML; Bigelow GE
    J Pharmacol Exp Ther; 1998 May; 285(2):387-96. PubMed ID: 9580575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions.
    Eissenberg T; Stitzer ML; Bigelow GE; Buchhalter AR; Walsh SL
    J Pharmacol Exp Ther; 1999 May; 289(2):936-45. PubMed ID: 10215673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
    Correia CJ; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous and oral l-alpha-acetylmethadol: pharmacodynamics and pharmacokinetics in humans.
    Walsh SL; Johnson RE; Cone EJ; Bigelow GE
    J Pharmacol Exp Ther; 1998 Apr; 285(1):71-82. PubMed ID: 9535996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. l-alpha-Acetylmethadol, l-alpha-acetyl-N-normethadol and l-alpha-acetyl-N,N-dinormethadol: comparisons with morphine and methadone in suppression of the opioid withdrawal syndrome in the dog.
    Vaupel DB; Jasinski DR
    J Pharmacol Exp Ther; 1997 Nov; 283(2):833-42. PubMed ID: 9353405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic l-alpha-acetylmethadol (LAAM) in rhesus monkeys: tolerance and cross-tolerance to the antinociceptive, ventilatory, and rate-decreasing effects of opioids.
    Brandt MR; France CP
    J Pharmacol Exp Ther; 2000 Jul; 294(1):168-78. PubMed ID: 10871309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic l-alpha acetylmethadol in rhesus monkeys: discriminative stimulus and other behavioral measures of dependence and withdrawal.
    Brandt MR; France CP
    J Pharmacol Exp Ther; 1998 Dec; 287(3):1029-37. PubMed ID: 9864289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction.
    Wolstein J; Gastpar M; Finkbeiner T; Heinrich C; Heitkamp R; Poehlke T; Scherbaum N
    Pharmacopsychiatry; 2009 Jan; 42(1):1-8. PubMed ID: 19153939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.
    Donny EC; Walsh SL; Bigelow GE; Eissenberg T; Stitzer ML
    Psychopharmacology (Berl); 2002 May; 161(2):202-12. PubMed ID: 11981600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis.
    Newcombe DA; Bochner F; White JM; Somogyi AA
    Drug Alcohol Depend; 2004 Oct; 76(1):63-72. PubMed ID: 15380290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans.
    Walsh SL; Sullivan JT; Preston KL; Garner JE; Bigelow GE
    J Pharmacol Exp Ther; 1996 Nov; 279(2):524-38. PubMed ID: 8930154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1988 Aug; 246(2):441-8. PubMed ID: 2457074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients.
    Oliveto A; Poling J; Sevarino KA; Gonsai KR; McCance-Katz EF; Stine SM; Kosten TR
    Drug Alcohol Depend; 2005 Aug; 79(2):157-65. PubMed ID: 16002025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute administration of buprenorphine in humans: partial agonist and blockade effects.
    Walsh SL; Preston KL; Bigelow GE; Stitzer ML
    J Pharmacol Exp Ther; 1995 Jul; 274(1):361-72. PubMed ID: 7542336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans.
    Carroll CP; Walsh SL; Bigelow GE; Strain EC; Preston KL
    Exp Clin Psychopharmacol; 2006 May; 14(2):109-20. PubMed ID: 16756415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.
    Petry NM; Bickel WK; Badger GJ
    Clin Pharmacol Ther; 1999 Sep; 66(3):306-14. PubMed ID: 10511067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental toxicity of levo-alpha-acetylmethadol (LAAM) in tolerant rats.
    York RG; Denny KH; Moody DE; Alburges ME
    Int J Toxicol; 2002; 21(2):147-59. PubMed ID: 12022632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in sensitivity to the rate-decreasing effects of opioids in pigeons treated acutely or chronically with l-alpha-acetylmethadol.
    Gerak LR; France CP
    J Pharmacol Exp Ther; 1997 May; 281(2):799-809. PubMed ID: 9152388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status.
    Anglin MD; Conner BT; Annon J; Longshore D
    Addiction; 2007 Sep; 102(9):1432-42. PubMed ID: 17697277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.